Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Biogen Inc.NASDAQ: BIIB
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$319.5M, compared with $634.8M a year earlier. Trailing-twelve-month net income was $417.6M. Over 3 fiscal years it compounded at -24.1% a year.
Context
- Net income amounted to 13.2% of revenue in FY2025, down 3.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 26 analysts of $1.86B (+43.8%) for the fiscal year ending Dec 2026, a step up from the -20.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$319.5M-200.0% QoQ
- Last fiscal yearDec 2025
- $1.29B-20.8% YoY
- LTMJun 2026
- $417.6M-72.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -150.3% | -36.9% | +113.4 pp |
| 1 year | -20.8% | +43.8% | +64.6 pp |
| 3-year CAGR | -24.1% | +28.0% | +52.2 pp |
| 5-year CAGR | +18.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.29B USD
- Year-over-year change
- -20.8%
- 4-year CAGR
- -7.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.29B | -20.8% |
| FY2024 | 2024-12-31 | 1.63B | +40.5% |
| FY2023 | 2023-12-31 | 1.16B | -60.8% |
| FY2022 | 2022-12-31 | 2.96B | +71.4% |
| FY2021 | 2021-12-31 | 1.73B | — |
Net Income vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 net income of $417.6M is the 10th largest of the 11 companies compared; the peer median is $4.35B.
- Its year-over-year change of -72.7% is the 10th highest of 11, against a peer median of +18.3%.
- Net income amounts to 4.2% of revenue for BIIB, versus a peer median of 25.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $26.71B | +93.6% | +49.0% | 33.5% | |
| LTM Sep 2026 | $11.82B | +15.4% | +59.9% | 19.0% | |
| LTM Jun 2026 | $8.74B | +32.1% | +5.6% | 22.9% | |
| LTM Jun 2026 | $4.41B | +21.1% | +6.0% | 34.9% | |
| LTM Jun 2026 | $4.37B | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | $4.33B | -2.9% | +1.3% | 27.9% | |
| LTM Jun 2026 | $1.31B | +5.5% | +22.4% | 41.6% | |
| LTM Jun 2026 | $807.99M | +353.2% | — | 16.8% | |
| LTM Sep 2026 | $546.15M | +113.1% | +12.2% | 56.9% | |
| LTM Jun 2026 | $417.6M | -72.7% | -24.1% | 4.2% | |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| Peer median (excluding BIIB) | $4.35B | +18.3% | +9.1% | 25.4% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| Deferred Income Tax | (426.8M) | (168.6M) | (305.8M) | (158.1M) | 361.6M |
| Stock-Based Compensation | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M |
| Change in Working Capital | (145.5M) | (890.3M) | (648.7M) | (155.2M) | (1.06B) |
| Accounts Receivables | 326M | (222.4M) | 56.7M | 194.2M | 42.1M |
| Inventory | (462.4M) | (320.2M) | (130.9M) | (273.8M) | (64.7M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (9.1M) | (347.7M) | (574.5M) | (75.6M) | (1.04B) |
| Other Non-Cash Items | 1.76B | (1.29B) | 581.2M | 592.2M | 537M |
| Operating Cash Flow | 3.64B | 1.38B | 1.55B | 2.88B | 2.2B |
| Capital Expenditures | (258.1M) | (240.3M) | (311.4M) | (359.8M) | (153.8M) |
| Acquisitions (Net) | 28.1M | 595M | (6.91B) | (1.07B) | 0 |
| Purchases of Investments | (3.81B) | (3.45B) | (5.14B) | 0 | (1.26B) |
| Sales of Investments | 3.5B | 4.66B | 8.29B | 551.5M | 79.7M |
| Other Investing Activities | 12.9M | 24.4M | (11.3M) | 83.9M | (38.7M) |
| Investing Cash Flow | (563.7M) | 1.59B | (4.09B) | (799.2M) | (1.37B) |
| Debt Repayment | (170M) | (1B) | 187.3M | (650M) | (16.9M) |
| Common Stock Issued | (700K) | (1.9M) | (44.3M) | (31.3M) | (10M) |
| Common Stock Repurchased | (1.8B) | (750M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (115.5M) | (5.6M) | (6M) | (2.2M) | (275M) |
| Financing Cash Flow | (2.09B) | (1.76B) | 137M | (683.5M) | (301.9M) |
| Effect of Forex Changes | (59.8M) | (55.7M) | 35.1M | (67.7M) | 101.9M |
| Net Change in Cash | 930.2M | 1.16B | (2.37B) | 1.33B | 633.5M |
| Free Cash Flow | 3.38B | 1.14B | 1.24B | 2.52B | 2.05B |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.